Randomized Controlled Clinical Trial of Hyperthermia and Hydrogen Peroxide 3% in the Treatment of Cutaneous Warts

Launched by FIRST HOSPITAL OF CHINA MEDICAL UNIVERSITY · Feb 2, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment for warts, specifically using a combination of heat and a mild disinfectant. The researchers want to see if warming the skin to a temperature of 44°C (about 111°F) along with applying 3% hydrogen peroxide can effectively help clear viral warts. Warts are caused by the human papillomavirus (HPV), and the hope is that this approach will help the body fight off the virus more effectively than standard treatments.

To participate in this trial, you need to be between 16 and 65 years old and have a clinical diagnosis of viral warts, which can include common warts or plantar warts. It’s important to note that certain conditions may prevent you from participating, such as having a weakened immune system or having had specific treatments for warts recently. If you join, you can expect to receive the heat and hydrogen peroxide treatment during the study and will be monitored for both effectiveness and any side effects. This trial is currently looking for volunteers, so if you're interested and meet the criteria, you could help contribute to important research on wart treatment.

Gender

ALL

Eligibility criteria

• • Inclusion criteria: The participants were between 16 and 65 years of age, had a clinical diagnosis of viral warts (including common warts, plantar warts, or condyloma acuminatum), and could understand and sign informed consent.
• • Exclusion criteria: presented with clinically atypical warts; had immunocompromised status or a history of HIV infection; received HPV vaccination within the past 6 months; used immunomodulators, immunosuppressants, or systemic corticosteroids within defined timeframes (4 months and 1 month, respectively); underwent local therapies (e.g., laser, cryotherapy, retinoids) on or near warts within protocol-specified intervals; had a history of cutaneous malignancies or current precancerous lesions; exhibited active dermatologic/systemic diseases (e.g., psoriasis, eczema) or skin conditions (e.g., sunburn) potentially increasing study risks; or were deemed ineligible by investigators for other medical or logistical reasons.